/ Headline earnings per share (basic and diluted)
| (in millions of euros, except for share data) |
not-included |
2023 |
2022 |
| Net income used to calculate headline earnings per share(1) |
unspecified |
unspecified |
unspecified |
| Net income – Group share |
unspecified |
1,312 |
1,222 |
| Items excluded: |
unspecified |
unspecified |
unspecified |
| Amortization of intangibles from acquisitions, net of tax |
unspecified |
199 |
215 |
| Impairment loss(2), net of tax |
unspecified |
115 |
80 |
| Main capital gains and losses on disposal of assets and fair value adjustment of financial assets, net of tax |
unspecified |
1 |
92 |
| Revaluation of earn‑out payments |
unspecified |
(12) |
2 |
| Rosetta / Publicis Health, LLC settlement (see Note 8 and Note 22) |
unspecified |
152 |
- |
| Headline Group net income |
E |
1,767 |
1,611 |
| Impact of dilutive instruments: |
unspecified |
unspecified |
unspecified |
| Savings in financial expenses related to the conversion of debt instruments, net of tax |
unspecified |
- |
- |
| Headline Group net income, diluted |
F |
1,767 |
1,611 |
| Number of shares used to calculate earnings per share |
unspecified |
unspecified |
unspecified |
| Number of shares at January 1 |
unspecified |
254,311,860 |
253,462,409 |
| Shares created over the year |
unspecified |
- |
393,965 |
| Treasury shares to be deducted (average for the year) |
unspecified |
(3,605,375) |
(2,884,264) |
| Average number of shares used for the calculation |
C |
250,706,485 |
250,972,110 |
| Impact of dilutive instruments: |
unspecified |
unspecified |
unspecified |
| Free shares and dilutive stock options |
unspecified |
3,292,878 |
2,633,057 |
| Number of diluted shares |
D |
253,999,363 |
253,605,167 |
| (in euros) |
unspecified |
unspecified |
unspecified |
| Headline earnings per share (1) |
E/C |
7.05 |
6.42 |
| Headline earnings per share – diluted (1) |
F/D |
6.96 |
6.35 |
